tm logo
CANTEX
Live/Pending
SUSPENSION LETTER - MAILED

mailed

on 17 Oct 2024

Last Applicant/ Owned by

1792 Bell Tower Lane

Weston

FL

33326

Serial Number

98043024 filed on 14th Jun 2023

Registration Number

N/A

Correspondent Address

Michael J. Belliveau

Michael J. Belliveau Clark+Elbing LLP

Boston, MA 02110

United States

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

CANTEX

Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Development of new drugs for the prevention and treatment of cancer and other serious illnesses; Design and testing of new drugs and therapies; Medical and scientific research in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, Read More

Classification Information


Class [045]
Personal & Legal & Social Services


Licensing of pharmaceuticals and drug discovery technologies


First Use Date in General

N/A

First Use Date in Commerce

N/A

Class [044]
Medical, Beauty & Agricultural Services


Providing medical and scientific research information about the diagnosis and treatment of diseases, namely, infectious diseases, viral diseases, and autoimmune diseases; Providing information in the fields of health, wellness, and pharmaceuticals via a website; all of the foregoing related to Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses


First Use Date in General

N/A

First Use Date in Commerce

N/A

Class [042]
Computer & Software Services & Scientific Services


Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Development of new drugs for the prevention and treatment of cancer and other serious illnesses; Design and testing of new drugs and therapies; Medical and scientific research in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Medical and scientific research consulting in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Biological testing and research in the field of pharmaceuticals; all of the foregoing related to Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases


First Use Date in General

N/A

First Use Date in Commerce

N/A

Class [005]
Pharmaceutical Products


Pharmaceuticals, namely, Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses; Pharmaceutical preparations for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for inhibiting Receptor for Advanced Glycation End products (RAGE) interactions, for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Pharmaceutical preparations for use in personalized medicine and targeted therapy in the field of Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases


First Use Date in General

N/A

First Use Date in Commerce

N/A

Mark Details


Serial Number

No 98043024

Mark Type

No Service Mark

Attorney Docket Number

No 51849-T02001

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
28th Oct 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
28th Oct 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
28th Oct 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
28th Oct 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
28th Oct 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
23rd Oct 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED
23rd Oct 2024WITHDRAWAL OF ATTORNEY GRANTED
17th Oct 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
17th Oct 2024SUSPENSION LETTER WRITTEN
17th Oct 2024LETTER OF SUSPENSION E-MAILED